8.27
0.73%
0.06
After Hours:
8.27
Theravance Biopharma Inc stock is traded at $8.27, with a volume of 127.66K.
It is up +0.73% in the last 24 hours and up +2.10% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$8.21
Open:
$8.26
24h Volume:
127.66K
Relative Volume:
0.46
Market Cap:
$402.20M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
0.728
EPS:
11.36
Net Cash Flow:
$-9.60M
1W Performance:
-4.39%
1M Performance:
+2.10%
6M Performance:
-12.58%
1Y Performance:
-16.04%
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-23-22 | Initiated | SVB Leerink | Outperform |
Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jul-07-20 | Initiated | JP Morgan | Overweight |
Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
May-13-20 | Initiated | Cowen | Outperform |
Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
Oct-29-19 | Initiated | H.C. Wainwright | Buy |
Mar-29-18 | Resumed | Piper Jaffray | Overweight |
Aug-17-17 | Initiated | Evercore ISI | Outperform |
Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
May-11-17 | Reiterated | Needham | Buy |
Dec-21-16 | Initiated | Needham | Buy |
Nov-03-16 | Initiated | Piper Jaffray | Overweight |
Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jun-20-16 | Initiated | Guggenheim | Buy |
Jun-20-16 | Reiterated | Leerink Partners | Outperform |
May-12-16 | Initiated | Leerink Partners | Outperform |
May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Theravance Biopharma (TBPH) Scheduled to Post Earnings on Tuesday - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Theravance Biophar - GuruFocus.com
(TBPH) Proactive Strategies - Stock Traders Daily
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by SG Americas Securities LLC - MarketBeat
When (TBPH) Moves Investors should Listen - Stock Traders Daily
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 - StockTitan
Q3 EPS Estimate for Theravance Biopharma Boosted by Analyst - MarketBeat
Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - Defense World
What is Zacks Research's Estimate for TBPH Q4 Earnings? - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by Analysts - MarketBeat
The Manufacturers Life Insurance Company Decreases Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance study shows YUPELRI improves COPD lung function By Investing.com - Investing.com Australia
Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat
Theravance study shows YUPELRI improves COPD lung function - Investing.com
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease - StockTitan
Where are the Opportunities in (TBPH) - Stock Traders Daily
Dimensional Fund Advisors LP Has $2.80 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma (STU:0TB) Price-to-Operating-Cash-Flow : (As of Oct. 10, 2024) - GuruFocus.com
Squarepoint Ops LLC Takes $986,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Bank of Montreal Can Raises Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Holdings Lifted by Marshall Wace LLP - MarketBeat
(TBPH) Pivots Trading Plans and Risk Controls - Stock Traders Daily
XTX Topco Ltd Purchases New Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y - MSN
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Rhumbline Advisers Sells 15,095 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
An Analysis of Theravance Biopharma Inc (TBPH)’s Potential Price Growth - Knox Daily
Theravance Biopharma settles patent litigation with Qilu Pharmaceutical - Investing.com
Baupost Group LLC MA Decreases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright maintains Buy rating on Theravance Biopharma shares By Investing.com - Investing.com Canada
Theravance Biopharma (NASDAQ:TBPH) Earns Buy Rating from HC Wainwright - MarketBeat
Unveiling 4 Analyst Insights On Theravance Biopharma - Benzinga
How To Trade (TBPH) - Stock Traders Daily
Leerink Partners gives a Market perform recommendation for Theravance Biopharma Inc (TBPH) - Knox Daily
Seth Klarman's Complete Exit from Theravance Biopharma Inc - Yahoo Finance
Theravance Biopharma Outlines Growth Strategy at Investment Conference - TipRanks
Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation - Yahoo Finance
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Theravance Biopharma Inc (TBPH) receives a Market perform rating from Leerink Partners - Knox Daily
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of “Hold” by Analysts - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Target Price from Analysts - MarketBeat
Q3 2024 EPS Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH) Reduced by Analyst - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 50-Day Moving Average of $8.90 - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) to Post Q4 2025 Earnings of $0.41 Per Share, Zacks Research Forecasts - Defense World
Zacks Research Brokers Increase Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizentribune
Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Below Fifty Day Moving Average of $8.90 - Defense World
TBPH Stock Earnings: Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024 - MSN
Leerink Partners Downgrades Theravance Biopharma Inc (TBPH) to a Market perform from an Outperform - Knox Daily
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Theravance Biopharma Inc Stock (TBPH) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Jul 10 '24 |
Sale |
9.00 |
4,000 |
36,000 |
335,965 |
Samaha Eli | 10% Owner |
May 01 '24 |
Buy |
8.75 |
1,499,124 |
13,117,335 |
8,511,350 |
Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Feb 22 '24 |
Sale |
8.71 |
1,254 |
10,922 |
311,733 |
Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Nov 21 '23 |
Sale |
10.29 |
1,378 |
14,180 |
331,206 |
GRAHAM RICHARD A | SVP, RESEARCH & DEVELOPMENT |
Nov 14 '23 |
Sale |
10.22 |
2,482 |
25,366 |
346,839 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):